FINWIRES · TerminalLIVE
FINWIRES

Johnson Controls Q3 Earnings Quality 'Impressive,' RBC Says

By

Johnson Controls International (JCI) reported a strong operating beat in fiscal Q3 and raised its 2026 earnings outlook above consensus, RBC Capital Markets said in a Wednesday note.

"The quality of earnings was impressive, including +45% incrementals," the report said.

The note said datacenter business drove the strong 27% total-company order growth from a year ago, and a record $21 billion backlog, up 32% organically.

"JCI's multi-year turnaround story continues to gain traction off its successful June-2026 investor day where they increased

their long-term organic growth algorithm," the report said.

RBC raised its price target to $161 from $154 while keeping its sector perform rating.

Price: $142.66, Change: $+3.24, Percent Change: +2.32%

Related Articles

Wire

Houlihan Lokey Fiscal Q1 Adjusted Earnings, Revenue Fall; Shares Drop After Hours

Houlihan Lokey (HLI) reported fiscal Q1 adjusted earnings late Wednesday of $1.35 per diluted share, down from $2.14 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $511 million from $605 million a year earlier.Analysts expected $602.4 million.Houlihan Lokey shares fell 6.6% in after-hours trading.

$HLI
Wire

Four Corners Property Trust Q2 AFFO, Revenue Rise

Four Corners Property Trust (FCPT) reported Q2 adjusted funds from operations late Wednesday of $0.45 per diluted share, up from $0.44 a year earlier.Analysts polled by FactSet expected $0.45.Revenue in the quarter ended June 30 rose to $78.4 million from $72.8 million a year earlier.Four analysts expected $79 million.The company's shares rose 2% in after-hours trading.

$FCPT
Wire

Corcept Therapeutics Q2 Earnings, Revenue Rise; Shares Jump After Hours

Corcept Therapeutics (CORT) reported Q2 earnings late Wednesday of $0.36 per diluted share, up from $0.29 a year earlier.Analysts polled by FactSet expected $0.02.Revenue for the three months ended June 30 rose to $256.1 million from $194.4 million a year earlier.Analysts expected $221.1 million.The company boosted full-year revenue guidance to $1.1 billion to $1.2 billion from the prior forecast of $950 million to $1.05 billion.Analysts project $999.5 million.Corcept shares jumped 18% in after-hours trading.

$CORT